每年万亿医保基金如何支持创新药？国家医保局详解

Core Viewpoint - The article emphasizes the importance of the National Medical Insurance Fund in supporting innovative pharmaceuticals in China, highlighting a stable funding source for the industry and the introduction of new drug listings in the medical insurance catalog [3][5]. Group 1: Medical Insurance Fund and Innovation - The National Medical Insurance Fund spends over 1 trillion yuan annually on pharmaceuticals, which is crucial for supporting medical innovation [3]. - During the 2025 Innovation Drug High-Quality Development Conference, it was stated that the cumulative expenditure of the National Medical Insurance Fund during the 14th Five-Year Plan period is approximately 13 trillion yuan, with an annual growth rate exceeding 10% [3][5]. - The National Medical Insurance Bureau announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, including 50 innovative drugs, achieving an overall success rate of 88% [3][5]. Group 2: Commercial Insurance and Drug Listings - The introduction of the commercial insurance innovative drug catalog is seen as a significant step towards the collaborative development of basic medical insurance and commercial insurance [7][8]. - The first edition of the commercial insurance innovative drug catalog includes 19 drugs, focusing on high clinical value and significant patient benefits, which are beyond the scope of basic medical insurance [8]. - The commercial health insurance sector has seen substantial growth, with premium income reaching 977.4 billion yuan in 2024, indicating a shift towards more diverse medical insurance products [8]. Group 3: Drug Coverage and Market Dynamics - The basic medical insurance has covered 44% of innovative drug payments, while commercial insurance accounts for 7%, indicating that basic medical insurance remains the primary payer for innovative drugs [6]. - Over the past eight years, the basic medical insurance drug list has seen a 40% increase in the number of drugs compared to before the establishment of the National Medical Insurance Bureau in 2018 [6]. - The collaboration between basic medical insurance and commercial insurance is essential, as basic insurance focuses on fundamental coverage while commercial insurance can address personalized needs and preferences [9].